"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One

In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.